aripiprazole has been researched along with amitriptyline in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Sen, S; Sinha, N | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Altamura, C; Arzuaga, A; Ciranna, L; Costa, L; Desaphy, JF; Lacivita, E; Leopoldo, M; Niso, M; Ragozzino, ME; Stama, ML | 1 |
Choudhary, PP; Munda, S; Pattojoshi, A; Prakash, R | 1 |
Motomura, H; Takenoshita, M; Toyofuku, A | 1 |
Arnold, LE; Han, JC; Hellings, JA | 1 |
2 review(s) available for aripiprazole and amitriptyline
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.
Topics: Adolescent; Adult; Amitriptyline; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Brain-Derived Neurotrophic Factor; Child; Dopamine Antagonists; Humans; Irritable Mood; Loxapine; Risperidone | 2017 |
6 other study(ies) available for aripiprazole and amitriptyline
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Privileged scaffold-based design to identify a novel drug-like 5-HT
Topics: Dose-Response Relationship, Drug; Drug Design; Fragile X Syndrome; HEK293 Cells; Humans; Molecular Structure; Piperazines; Receptors, Serotonin; Serotonin Receptor Agonists; Structure-Activity Relationship | 2020 |
Benign clinical picture after ingestion of 780 milligrams of aripiprazole and 1050 milligrams of amitriptyline.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Drug Overdose; Humans; Male; Piperazines; Quinolones; Suicide, Attempted | 2009 |
Low-Dose Aripiprazole Augmentation in Amitriptyline-Resistant Burning Mouth Syndrome: Results from Two Cases.
Topics: Aged; Amitriptyline; Analgesics, Non-Narcotic; Antipsychotic Agents; Aripiprazole; Burning Mouth Syndrome; Drug Therapy, Combination; Female; Humans; Middle Aged | 2017 |